Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to study the relationship between the bile acids, short chain fatty acids and bacteria within the intestines. The hypothesis is that changes in the bacterial composition of the stool are associated with the differences in bile acids and short chain fatty acids in patients having irritable bowel syndrome compared to healthy individuals.


Clinical Trial Description

The Study involves 3 visits and will in include 3 types of subjects - those who have irritable bowel syndrome (IBS) with constipation (IBS-C), IBS with diarrhea (IBS-D) and those who have no IBS symptoms or diagnosis. Visit 1 - Volunteers will read and sign this informed consent after all questions about the study have been answered - This is a screening visit and we may determine that volunteers ineligible to continue to participate in the study. - Volunteers will have a medical history taken including demographics, history of symptoms and illness - Volunteers will be asked about all medications - A physical exam will be performed by the physician. - Vital signs will be measured. - Urine Pregnancy test may be done for woman in the reproductive age range. - Eligible participants will be provided with a take-home lasagna meal. - Participants will be given instructions and supplies for collection, storage and transportation of stool for the next visit. - Participants will be provided with instructions for a low fiber, high fat diet which should be consumed for 2 days before stool collection and during the 2 days of stool collection. Instructions will also come with materials to allow participants to record diet intake during these 4 days. - Participants will be provided a bowel pattern diary to record bowel symptoms over the course of the study Day 1: this may be the same as Visit 1 or it may be a different day. It will depend upon the day that participants can make it back to the clinic for the Day 5 visit. Day 2-4 (at home): - Participants record stool symptoms and patterns in a diary daily starting from Day 2 to Day 5. - During this time, participants will be instructed to consume a low fiber diet, avoid alcohol, and start a 4-day 100 g fat diet. - On the evening before Day 5, a standardized, completely digestible, and non-fermentable meal (lasagna) will be consumed which will be provided to you on Day 1. - Participants will collect stool at home on Day 4 and 5 and store as per instructions provided on Visit 1. They will Day 5 (Visit 2): - Participants return to the clinic on Day 5 after an overnight fast. - You will receive a standard breakfast and lasanga meal with 10 g inulin (Orafti®) powder and 200 mL of water. - Take-home meals will be provided (white bread sandwich with ham or cheese) to be consumed at 4 and 8 hours after breakfast. Day 6 (Visit 3): - Participants will return to the clinic in order to return stool collections and the daily diaries. - Participants may also submit diaries by fax or email. Day 30-90 • Optional dietary follow-up (Day 30-90): To further assess the utility of the 24 hour dietary recall, willing participants will be invited to participate in a an optional follow-up activity during which they will complete the Automated Self-Administered Dietary Assessment Tool with or without assistance of a trained interviewer. Interested volunteers will be contacted by phone and provided instructions on how to complete the tool online by the study team. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03983434
Study type Interventional
Source Indiana University
Contact
Status Active, not recruiting
Phase N/A
Start date August 13, 2019
Completion date June 2, 2024

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05118243 - Innovative Tools to Produce Legume-based Foods for Increased Consumer Acceptance N/A
Completed NCT04422327 - The Impact of a Combination of Bifidobacterium Longum 35624® and 1714™ Strains in Adults With Irritable Bowel Syndrome Phase 1/Phase 2
Recruiting NCT05178017 - Lifestyle Eating and Performance (LEAP) Program for the Treatment of Irritable Bowel Syndrome (IBS) N/A
Completed NCT05197413 - Study to Evaluate the Efficacy of Arrae's Bloat & Calm Alchemy Capsules to Reduce Bloating, Heartburn and Gas, and Alleviate the Intensity of IBS Symptoms N/A
Completed NCT04905524 - Activity Changes in Irritable Bowel Syndrome (IBS), Anxiety, and Depression Following the Use of Viome Precision Nutrition Program (VPNP) N/A
Recruiting NCT06297785 - Online, Gut-directed Hypnotherapy for Patients With Irritable Bowel Syndrome (IBS) N/A
Recruiting NCT05874830 - The Optimal Route of Fecal Microbiota Transplantation for Irritable Bowel Syndrome N/A
Active, not recruiting NCT04723056 - Zemedy Application for Irritable Bowel Syndrome N/A
Completed NCT05565612 - Clinical Trial to Evaluate the Effect of a Probiotic Mixture on Signs and Symptoms of Irritable Bowel Syndrome N/A
Recruiting NCT03131414 - The IMAGINE-SPOR CIHR Chronic Disease Network
Completed NCT03333291 - Fecal Transplantation in Patients With IBS N/A
Completed NCT03449628 - L. Casei DG® in Patients With Irritable Bowel Syndrome. N/A
Recruiting NCT06215222 - Capsule Microbiota Sampling in IBS/Functional Gastrointestinal Disease
Completed NCT05016596 - Postprandial Lipids in IBS and Nutritional Treatment N/A
Recruiting NCT04760353 - The Effect of a Probiotic Mixture in Obese Patients With Irritable Bowel Syndrome N/A
Recruiting NCT04217733 - Ethosuximide and Pentoxifylline in the Treatment of Abdominal Pain Related to Irritable Bowel Syndrome Phase 3
Completed NCT03178877 - The Prevalence of Irritable Bowel Syndrome Using Rome IV Criteria in Medical Student and The Related Factors N/A
Recruiting NCT05990764 - Effects of a Combination of Polyphenol-rich Extracts, Prebiotics, and Hydrolyzed Fiber on the Quality of Life of Patients With Irritable Bowel Syndrome (IBS) N/A
Completed NCT03948854 - Implementing a Low FODMAP Diet in Irritable Bowel Syndrome Patients N/A
Completed NCT04898257 - Effect of Lactibiane Tolerance® to Treat Leaky Gut in Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D)Patients N/A